Similarly, Chesi and colleagues recently showed that aside from their effect as inducers of apoptosis, SMAC mimetic (IAP antagonists) were able to induce anti-tumour immunity by modulating the NF-κB response in immune cells in the tumour microenvironment (Chesi et al, 2016). This evidence concerns the gene NFKB1 and neoplasm.